Revvity

Business

Revvity Beats 2025 Forecasts on Diagnostics Strength, Offers Cautious 2026 Outlook

Life sciences and diagnostics firm Revvity (RVTY) closed 2025 with results surpassing internal targets, driven by robust diagnostics performance. While management provided initial 2026 guidance, it remains conservative, banking on market stabilization rather than a broad recovery.

Business

Revvity Beats Q4 Forecasts, Sets Bullish 2026 Targets on Diagnostics Strength

Revvity (NYSE: RVTY) surged past fourth-quarter expectations and issued an upbeat 2026 outlook, driven by robust demand in its diagnostics division. The medical equipment maker's performance highlights a sector-wide resilience despite ongoing softness in academic research funding.